Clinical trials: Tetanus, open to volunteers
Pertussis, Diphtheria
Study of BK1803 in Healthy Infants
This study is a phase 3, randomized, observer-blinded, active-controlled, multicenter study to evaluate the immunogenicity and safety of BK1803 in healthy infants aged 2 months to less than 7 months.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT07793513
- Testing
- BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection
- Where
- 33 sites in Japan
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design.
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
- Trial name
- NCT07203755
- Testing
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Prevent Whooping Cough, Prevent Diphtheria
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months.
- Conditions
- Prevent Whooping Cough, Prevent Diphtheria, Prevent Tetanus
- Trial name
- NCT07112144
- Testing
- DTacP, DTaP, DTacP-IPV/Hib
- Where
- China
- Volunteers
- 1,650 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Pneumococcal Infections, Streptococcal Infections
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07648641
- Testing
- Previously vaccinated with PCV13 (CanSino), Previously vaccinated with PCV13 (Pfizer)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Healthy Volunteers
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants.
- Trial name
- NCT06344065
- Testing
- Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed), Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine
- Where
- China
- Volunteers
- 1,584 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Tetanus-diphtheria-acellular Pertussis (Tdap)
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity).
- Trial name
- NCT06997627
- Testing
- GC3111B, Boostrix®
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Diptheria Immunization, Tetanus Immunization
Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)
This is a Phase I/II, double-blind, randomized, active controlled, multi-centric clinical trial to assess the reactogenicity, safety and immunogenicity of a SIIPL DTwP-HepB-rPV-Hib vaccine in comparison with HEXASIIL® in healthy…
- Conditions
- Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization
- Trial name
- NCT07855172
- Testing
- Hexavalent (DTwP-HepB-rPV-Hib) Vaccine, HEXASIIL
- Where
- Bangladesh
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Vaccine Delivery, Tetanus
A First in Human Study Investigating the Safety of an Unloaded and Loaded (With a Tetanus-containing Vaccine Booster) Microneedle Patch in Healthy Adults
The purpose of this research study is to check whether the MNS Miracus Patch (the study's investigational device, a small patch made up of microneedles that dissolve in the skin and can potentially deliver vaccines in a pain-free…
- Trial name
- Miracus™ FIH (NCT07624669)
- Testing
- Microneedle Patch, Tetanus-containing vaccine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Microneedle Solutions Ltd
Pertussis (Whooping Cough), Diphtheria
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07894055
- Testing
- Tdap vaccine
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Streptococcus Pneumoniae Infection
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months…
- Trial name
- NCT07600983
- Testing
- 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M)
- Where
- 2 sites in China
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Tetanus
A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Study sites were selected from hospitals across diverse regions of China. Approximately 6,000 participants who require passive immunization against tetanus due to various injuries (including those with severe wounds or heavily…
- Trial name
- NCT07347938
- Testing
- Siltartoxatug Injection, HTIG/TAT/F(ab')₂
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Tetanus
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred.
- Trial name
- NCT07107932
- Testing
- Siltartoxatug Injection (Brand name: Sintetol®)
- Where
- 4 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Tetanus
Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine
This study included 240 trial participants who had previously taken part in a Phase III clinical trial of an adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001), with 120 participants in each of the treatment and control…
- Trial name
- NCT07807033
- Testing
- Previously vaccinated with TTVA, Previously vaccinated with TT
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningococcal Immunization, Healthy Volunteers
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea
This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse…
- Trial name
- NCT07621653
- Testing
- Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine
- Where
- 9 sites in South Korea
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pertussis (Whooping Cough), Diphtheria
A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the safety and tolerability of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07492303
- Testing
- Tdap vaccine
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Tetanus
A Phase Ⅲ Clinical Study of SNA02-48 Injection
The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.
- Trial name
- NCT07633119
- Testing
- SNA02-48, Human tetanus immunoglobulin (HTIG)
- Where
- 30 sites in China
- Volunteers
- 600 people
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Tetanus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
A Randomized, Double-blind, Controlled, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Intramuscular Injection of Recombinant Human Anti-tetanus…
- Trial name
- NCT07149454
- Testing
- Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection, Human Tetanus Immunoglobulin
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to evaluate the safety, tolerability, and recommended dose of intraperitoneal (IP) administration of Lm-LLO-TT in combination with…
- Conditions
- Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT07828236
- Testing
- Lm-LLO-TT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Loki Therapeutics, Inc.
Diphtheria, Tetanus
A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine
This clinical trial will enroll 160 participants who previously took part in the Phase I clinical trial of the adsorbed acellular pentavalent (five-component) DTP-polio combination vaccine (for individuals aged 6 years and older)…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT07744347
- Testing
- Previously received the Tdcp vaccine at age 18 and older, Previously received the Tdcp vaccine at age 12-17, Previously received the Tdcp vaccine at age 6-11
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.